Author: "McCombe, Pamela" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"McCombe, Pamela"' showing total 885 results

Start Over Author "McCombe, Pamela"

885 results on '"McCombe, Pamela"'

101. Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms

Author: Greer, Judith M. and McCombe, Pamela A.
Published: 2011
Full Text: View/download PDF

102. Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis

Author: Cabrera-Serrano, Macarena, primary, Caccavelli, Laure, additional, Savarese, Marco, additional, Vihola, Anna, additional, Jokela, Manu, additional, Johari, Mridul, additional, Capiod, Thierry, additional, Madrange, Marine, additional, Bugiardini, Enrico, additional, Brady, Stefen, additional, Quinlivan, Rosaline, additional, Merve, Ashirwad, additional, Scalco, Renata, additional, Hilton-Jones, David, additional, Houlden, Henry, additional, Aydin, Halil Ibrahim, additional, Ceylaner, Serdar, additional, Drewes, Sarah, additional, Vockley, Jerry, additional, Taylor, Rhonda L, additional, Folland, Chiara, additional, Kelly, Aasta, additional, Goullee, Hayley, additional, Ylikallio, Emil, additional, Auranen, Mari, additional, Tyynismaa, Henna, additional, Udd, Bjarne, additional, Forrest, Alistair R R, additional, Davis, Mark R, additional, Bratkovic, Drago, additional, Manton, Nicholas, additional, Robertson, Thomas, additional, O’Gorman, Cullen, additional, McCombe, Pamela, additional, Laing, Nigel G, additional, Phillips, Liza, additional, de Lonlay, Pascale, additional, and Ravenscroft, Gianina, additional
Published: 2021
Full Text: View/download PDF

103. A Case Series of Patients With Autoimmune Myasthenia Gravis in Association With Invasive Thymoma

Author: McCombe, Pamela, Raj, Meenakshi, Henderson, Robert, and Blum, Stefan
Published: 2016
Full Text: View/download PDF

104. Age of Onset and Length of Survival of Queensland Patients with Amyotrophic Lateral Sclerosis: Details of Subjects with Early Onset and Subjects with Long Survival.

Author: Nona, Robert J., Xu, Zhouwei, Robinson, Gail A., Henderson, Robert D., and McCombe, Pamela A.
Subjects: AMYOTROPHIC lateral sclerosis, AGE of onset, WOMEN'S hospitals
Abstract: Introduction: The aims of the study were to document the characteristics of amyotrophic lateral sclerosis (ALS) patients in Queensland, to examine factors influencing age of onset, and survival, and to study those with early-onset (<45 years) disease and those with long (>5 years) survival. Methods: We studied subjects seen at the ALS Clinic at the Royal Brisbane and Women's Hospital. We recorded sex, age of onset, region of onset, length of survival, presence of family history, type of disease, and evidence of cognitive involvement. We analysed the influence of these features on age of onset and survival. We analysed the features of patients with early onset of disease and patients with long survival. Results: There were 855 ALS patients (505 males) in the cohort. The age of onset was lower in males than females, in patients with a family history of ALS compared to those without, and in patients with spinal onset compared to bulbar onset. Early-onset disease was seen in 10% of patients, and had a greater proportion of males, spinal onset, and classical ALS phenotype compared to late-onset disease. Survival was shorter in females, in patients with bulbar onset, and in patients with classical ALS. Long survival was seen in 18% of patients. Patients with long survival had younger age of onset, greater proportion of males, spinal onset, and fewer patients with classical ALS. Conclusion: Our study confirms that ALS is more prevalent in males and that spinal onset is more common than bulbar onset. Males have earlier onset but longer survival. We found that overall, patients with classical ALS have worse survival than ALS variants, but some patients who were considered to have classical ALS had long survival. This study confirms the similarity of ALS in our region to ALS in other geographical regions. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

105. Lower hypothalamic volume with lower body mass index is associated with shorter survival in patients with amyotrophic lateral sclerosis.

Author: Chang, Jeryn, Shaw, Thomas B., Holdom, Cory J., McCombe, Pamela A., Henderson, Robert D., Fripp, Jurgen, Barth, Markus, Guo, Christine C., Ngo, Shyuan T., and Steyn, Frederik J.
Subjects: AMYOTROPHIC lateral sclerosis, BODY mass index, OVERALL survival, WEIGHT loss, APPETITE loss
Abstract: Background and purpose: Weight loss in patients with amyotrophic lateral sclerosis (ALS) is associated with faster disease progression and shorter survival. Decreased hypothalamic volume is proposed to contribute to weight loss due to loss of appetite and/or hypermetabolism. We aimed to investigate the relationship between hypothalamic volume and body mass index (BMI) in ALS and Alzheimer's disease (AD), and the associations of hypothalamic volume with weight loss, appetite, metabolism and survival in patients with ALS. Methods: We compared hypothalamic volumes from magnetic resonance imaging scans with BMI for patients with ALS (n = 42), patients with AD (n = 167) and non‐neurodegenerative disease controls (n = 527). Hypothalamic volumes from patients with ALS were correlated with measures of appetite and metabolism, and change in anthropomorphic measures and disease outcomes. Results: Lower hypothalamic volume was associated with lower and higher BMI in ALS (quadratic association; probability of direction = 0.96). This was not observed in AD patients or controls. Hypothalamic volume was not associated with loss of appetite (p = 0.58) or hypermetabolism (p = 0.49). Patients with lower BMI and lower hypothalamic volume tended to lose weight (p = 0.08) and fat mass (p = 0.06) over the course of their disease, and presented with an increased risk of earlier death (hazard ratio [HR] 3.16, p = 0.03). Lower hypothalamic volume alone trended for greater risk of earlier death (HR 2.61, p = 0.07). Conclusion: These observations suggest that lower hypothalamic volume in ALS contributes to positive and negative energy balance, and is not universally associated with loss of appetite or hypermetabolism. Critically, lower hypothalamic volume with lower BMI was associated with weight loss and earlier death. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

106. High Caloric Diets in Amyotrophic Lateral Sclerois

Author: Ngo, Shyuan T., primary, Steyn, Frederik J., additional, McCombe, Pamela A., additional, and Borges, Karin, additional
Published: 2015
Full Text: View/download PDF

107. Effects of gender in amyotrophic lateral sclerosis

Author: McCombe, Pamela A. and Henderson, Robert D.
Published: 2010
Full Text: View/download PDF

108. Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Author: Maltby, Vicki E, primary, Lea, Rodney A, additional, Monif, Mastura, additional, Fabis-Pedrini, Marzena J, additional, Buzzard, Katherine, additional, Kalincik, Tomas, additional, Kermode, Allan G, additional, Taylor, Bruce, additional, Hodgkinson, Suzanne, additional, McCombe, Pamela, additional, Butzkueven, Helmut, additional, Barnett, Michael, additional, and Lechner-Scott, Jeannette, additional
Published: 2021
Full Text: View/download PDF

109. Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Author: Zhong, Michael, primary, van der Walt, Anneke, additional, Stankovich, Jim, additional, Kalincik, Tomas, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Boz, Cavit, additional, Hodgkinson, Suzanne, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Macdonell, Richard, additional, Prevost, Julie, additional, Kuhle, Jens, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Alroughani, Raed, additional, Kermode, Allan G, additional, Butler, Ernest, additional, Barnett, Michael, additional, Eichau, Sara, additional, van Pesch, Vincent, additional, Grammond, Pierre, additional, McCombe, Pamela, additional, Karabudak, Rana, additional, Duquette, Pierre, additional, Girard, Marc, additional, Taylor, Bruce, additional, Yeh, Wei, additional, Monif, Mastura, additional, Gresle, Melissa, additional, Butzkueven, Helmut, additional, and Jokubaitis, Vilija G, additional
Published: 2021
Full Text: View/download PDF

110. Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosis

Author: Holdom, Cory J., primary, Ngo, Shyuan T., additional, McCombe, Pamela A., additional, Henderson, Robert D., additional, and Steyn, Frederik J., additional
Published: 2021
Full Text: View/download PDF

111. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis

Author: Clarke, Laura, primary, Arnett, Simon, additional, Bukhari, Wajih, additional, Khalilidehkordi, Elham, additional, Jimenez Sanchez, Sofia, additional, O'Gorman, Cullen, additional, Sun, Jing, additional, Prain, Kerri M., additional, Woodhall, Mark, additional, Silvestrini, Roger, additional, Bundell, Christine S., additional, Abernethy, David A., additional, Bhuta, Sandeep, additional, Blum, Stefan, additional, Boggild, Mike, additional, Boundy, Karyn, additional, Brew, Bruce J., additional, Brownlee, Wallace, additional, Butzkueven, Helmut, additional, Carroll, William M., additional, Chen, Cella, additional, Coulthard, Alan, additional, Dale, Russell C., additional, Das, Chandi, additional, Fabis-Pedrini, Marzena J., additional, Gillis, David, additional, Hawke, Simon, additional, Heard, Robert, additional, Henderson, Andrew P. D., additional, Heshmat, Saman, additional, Hodgkinson, Suzanne, additional, Kilpatrick, Trevor J., additional, King, John, additional, Kneebone, Christopher, additional, Kornberg, Andrew J., additional, Lechner-Scott, Jeannette, additional, Lin, Ming-Wei, additional, Lynch, Christopher, additional, Macdonell, Richard A. L., additional, Mason, Deborah F., additional, McCombe, Pamela A., additional, Pereira, Jennifer, additional, Pollard, John D., additional, Ramanathan, Sudarshini, additional, Reddel, Stephen W., additional, Shaw, Cameron P., additional, Spies, Judith M., additional, Stankovich, James, additional, Sutton, Ian, additional, Vucic, Steve, additional, Walsh, Michael, additional, Wong, Richard C., additional, Yiu, Eppie M., additional, Barnett, Michael H., additional, Kermode, Allan G. K., additional, Marriott, Mark P., additional, Parratt, John D. E., additional, Slee, Mark, additional, Taylor, Bruce V., additional, Willoughby, Ernest, additional, Brilot, Fabienne, additional, Vincent, Angela, additional, Waters, Patrick, additional, and Broadley, Simon A., additional
Published: 2021
Full Text: View/download PDF

112. Venous creatinine as a biomarker for loss of fat‐free mass and disease progression in patients with amyotrophic lateral sclerosis

Author: Holdom, Cory J., primary, Janse van Mantgem, Mark R., additional, Eijk, Ruben P. A., additional, Howe, Stephanie L., additional, Berg, Leonard H., additional, McCombe, Pamela A., additional, Henderson, Robert D., additional, Ngo, Shyuan T., additional, and Steyn, Frederik J., additional
Published: 2021
Full Text: View/download PDF

113. 006 Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models

Author: Diouf, Ibrahima, primary, Malpas, Charles B, additional, Sharmin, Sifat, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Lechner-Scott, Jeannette, additional, Barnett, Michael, additional, Hodgkinson, Suzanne, additional, Slee, Mark, additional, Butler, Ernest, additional, McCombe, Pamela, additional, Walt, Anneke van der, additional, Butzkueven, Helmut, additional, Vucic, Steve, additional, Macdonell, Richard, additional, Shaw, Cameron, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

114. 008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis

Author: Roos, Izanne, primary, Malpas, Charles B, additional, Leray, Emmanuelle, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Lechner-Scott, Jeannette, additional, McCombe, Pamela, additional, Slee, Mark, additional, Butler, Ernest, additional, Macdonell, Richard, additional, Walt, Anneke van der, additional, Hodgkinson, Suzanne, additional, Barnett, Michael, additional, Vucic, Steve, additional, Vukusic, Sandra, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

115. 016 Genetic epidemiology of Motor Neuron Disease: Royal Brisbane and Women’s Hospital Cohort

Author: Yang, Po Sheng, primary, Henderson, Robert, additional, and McCombe, Pamela, additional
Published: 2021
Full Text: View/download PDF

116. 004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis

Author: Yeh, Wei Z, primary, Widyastuti, Putu A, additional, Walt, Anneke Van der, additional, Stankovich, Jim, additional, Havrdova, Eva K, additional, Horakova, Dana, additional, Vodehnalova, Karolina, additional, Ozakbas, Serkan, additional, Eichau, Sara, additional, Duquette, Pierre, additional, Kalincik, Tomas, additional, Patti, Francesco, additional, Boz, Cavit, additional, Terzi, Murat, additional, Yamout, Bassem, additional, Lechner-Scott, Jeannette, additional, Sola, Patrizia, additional, Skibina, Olga, additional, Barnett, Michael, additional, Onofrj, Marco, additional, Sá, Maria J, additional, McCombe, Pamela, additional, Grammond, Pierre, additional, Ampapa, Radek, additional, Grand’Maison, Francois, additional, Bergamaschi, Roberto, additional, Spitaleri, Daniele LA, additional, Pesch, Vincent Van, additional, Cartechini, Elisabetta, additional, Hodgkinson, Suzanne, additional, Soysal, Aysun, additional, Saiz, Albert, additional, Gresle, Melissa, additional, Uher, Tomas, additional, Maimone, Davide, additional, Turkoglu, Recai, additional, Hupperts, Raymond MM, additional, Amato, Maria Pia, additional, Granella, Franco, additional, Oreja-Guevara, Celia, additional, Altintas, Ayse, additional, Macdonell, Richard, additional, Castillo-Trivino, Tamara, additional, Butzkueven, Helmut, additional, Alroughani, Raed, additional, Jokubaitis, Vilija G, additional, and Registry, MSBase, additional
Published: 2021
Full Text: View/download PDF

117. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author: Andersen, Johanna B, primary, Sharmin, Sifat, additional, Lefort, Mathilde, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn, additional, Sørensen, Per Soelberg, additional, Hilt Christensen, Claudia C, additional, Rasmussen, Peter V, additional, Jensen, Michael B, additional, Frederiksen, Jette L, additional, Bramow, Stephan, additional, Mathiesen, Henrik K, additional, Schreiber, Karen I, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Skibina, Olga, additional, Solaro, Claudio, additional, Karabudak, Rana, additional, Wijmeersch, Bart V, additional, Csepany, Tunde, additional, Spitaleri, Daniele, additional, Vucic, Steve, additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Sèze, Jérôme D, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abdullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Marousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Leray, Emmanuelle, additional, Laplaud, David A, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Vukusic, Sandra, additional, and Magyari, Melinda, additional
Published: 2021
Full Text: View/download PDF

118. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Author: Kalincik, Tomas, Horakova, Dana, Spelman, Tim, Jokubaitis, Vilija, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Rozsa, Csilla, Grammond, Pierre, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Lechner-Scott, Jeannette, Slee, Mark, Fernandez-Bolanos, Ricardo, GrandʼMaison, Francois, Hupperts, Raymond, Verheul, Freek, Hodgkinson, Suzanne, Oreja-Guevara, Celia, Spitaleri, Daniele, Barnett, Michael, Terzi, Murat, Bergamaschi, Roberto, McCombe, Pamela, Sanchez-Menoyo, Jose, Simo, Magdolna, Csepany, Tunde, Rum, Gabor, Boz, Cavit, Havrdova, Eva, and Butzkueven, Helmut
Published: 2015
Full Text: View/download PDF

119. Immune activation in the peripheral blood of patients with acute ischemic stroke

Author: Yan, Jun, Greer, Judith M., Etherington, Kellie, Cadigan, Greg P., Cavanagh, Helen, Henderson, Robert D., O'Sullivan, John D., Pandian, Jeyaraj D., Read, Stephen J., and McCombe, Pamela A.
Published: 2009
Full Text: View/download PDF

120. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts

Author: Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Eva Kubala Havrdova, Alroughani, Raed, Ayuso, Guillermo Izquierdo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, Mccombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Walt, Anneke, Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele Litterio A., Vucic, Ostoja, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurelie, Seze, Jerome, Maillart, Elisabeth, Zephir, Helene, Labauge, Pierre, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanche, Jean-Philippe, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Celine, Nifle, Chantal, Laplaud, David, Koch-Henriksen, Nils, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Pfleger, Claudia Christina, Rasmussen, Peter Vestergaard, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas
Published: 2021

121. Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis

Author: Vitkova, Marianna, Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Eva Kubala Havrdova, Patti, Francesco, Ozakbas, Serkan, Izquierdo Ayuso, Guillermo, Eichau Madueno, Sara, Shaygannejad, Vahid, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Larochelle, Catherine, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand Maison, Francois, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Butzkueven, Helmut, Buzzard, Katherine, Skibina, Olga, Yamout, Bassem, Karabudak, Rana, Gerlach, Oliver H. H., Lechner-Scott, Jeannette, Maimone, Davide, Bergamaschi, Roberto, Pesch, Vincent, Iuliano, Gerardo, Cartechini, Elisabetta, Sa, Maria Jose, Ampapa, Radek, Barnett, Michael, Hughes, Stella, Ramo-Tello, Cristina, Hodgkinson, Suzanne, Spitareli, Daniele, Petersen, Thor, Butler, Ernest, Slee, Mark, Mcguigan, Christopher, Mccombe, Pamela, Granella, Franco, Cristiano, Edgardo, Prevost, Julie, Taylor, Bruce, Luis Sanchez-Menoyo, Jose, Laureys, Guy, Hijfte, Liesbeth, Vucic, Steve, Macdonell, Richard, Gray, Orla, Olascoaga Urtaza, Francisco Javier, Deri, Norma, Fragoso, Yara, Shaw, Cameron, and Kalincik, Tomas
Published: 2021

122. Sexual Dimorphism in the Immune System

Author: McCombe, Pamela A., primary and Greer, Judith M., additional
Published: 2014
Full Text: View/download PDF

123. List of Contributors

Author: Agmon-Levin, Nancy, primary, Ahmed, S. Sohail, additional, Ali, Youssif M., additional, Aringer, Martin, additional, Bach, Jean-François, additional, Barker, Jennifer, additional, Barker, Robert N., additional, Baxter, Alan G., additional, Betterle, Corrado, additional, Birlea, Stanca A., additional, Björkström, Niklas K., additional, Blair, Paul A., additional, Bobik, Alex, additional, Borazan, Nabeel H., additional, Bosch, Xavier, additional, Brodsky, Robert A., additional, Bryceson, Yenan T., additional, Burkett, Patrick R., additional, Bussel, James B., additional, Butzkueven, Helmut, additional, Caricchio, Roberto, additional, Casciola-Rosen, Livia, additional, Caturegli, Patrizio, additional, Chatenoud, Lucienne, additional, Cohen, Philip L., additional, Coppieters, Ken, additional, Crome, Sarah Q., additional, Crystal, Ronald G., additional, Culton, Donna A., additional, Dalal, Monica D., additional, David, Chella S., additional, Davidson, Anne, additional, Delli, Ahmed J., additional, Delves, Peter J., additional, Denmark, Vera Kandror, additional, Diamond, Betty, additional, Diaz, Luis A., additional, Eaton, John E., additional, Eisenbarth, George S., additional, Falk, Ronald J., additional, Field, Judith, additional, Fleisher, Thomas A., additional, Fragoulis, George E., additional, Fritzler, Marvin J., additional, Furst, Daniel E., additional, Gallucci, Stefania, additional, Gelbman, Brian, additional, Eric Gershwin, M., additional, Getts, Daniel R., additional, Getts, Meghann Teague, additional, Gianani, Roberto, additional, Gleeson, Paul A., additional, Goding, James W., additional, Gordon, Siamon, additional, Goronzy, Jörg J., additional, Greer, Judith M., additional, Gruson, Berengere, additional, Guilherme, L., additional, Gutenberg, Angelika, additional, Hafler, David A., additional, Hahn, Bevra H., additional, Hamano, Hideaki, additional, Hamilton, Sara R., additional, Harrison, Leonard C., additional, Hernandez, Amanda L., additional, Husebye, Eystein, additional, Charles Jennette, J., additional, Jones, Richard J., additional, Jordan, Margaret A., additional, Kalil, J., additional, Königs, Christoph, additional, Kawa, Shigeyuki, additional, Kaya, Ziya, additional, King, Jennifer K., additional, King, Nicholas J.C., additional, Kiyosawa, Kendo, additional, Kronenberg, Mitchell, additional, Kuchroo, Vijay K., additional, Kyaw, Tin, additional, Lünemann, Jan, additional, Lahita, Robert G., additional, Lalezari, Parviz, additional, Lambert, Paul-Henri, additional, Lancaster, Eric, additional, Laurence, Arian, additional, Lee, Youjin, additional, Lenardo, Michael, additional, Lernmark, Åke, additional, Levinson, Arnold I., additional, Lindor, Keith D., additional, Liu, Zhi, additional, Ljunggren, Hans-Gustaf, additional, Lunardi, Claudio, additional, Lundin, Knut E.A., additional, Lunn, Michael P.T., additional, Lupi, Isabella, additional, Lustig, Livia, additional, Münz, Christian, additional, Mackay, Charles R., additional, Mackay, Ian R., additional, Malattia, Clara, additional, Mangalam, Ashutosh, additional, Martini, Alberto, additional, Mauri, Claudia, additional, Mavragani, Clio P., additional, Mayer, Lloyd, additional, McCombe, Pamela A., additional, Melchers, Fritz, additional, Mieli-Vergani, Giorgina, additional, Miller, Frederick W., additional, Miller, Stephen D., additional, Mizui, Masayuki, additional, Mjösberg, Jenny, additional, Moutsopoulos, Haralampos M., additional, Norris, David A., additional, Nussenblatt, Robert B., additional, O’Connor, Kevin C., additional, Ohashi, Pamela S., additional, O’Keeffe, Meredith, additional, Oliveira, Joao Bosco, additional, Oppenheim, Joost J., additional, Perez-Arroyo, Alicia, additional, Peters, Anneli, additional, Peterson, Pärt, additional, Plüddemann, Annette, additional, Posner, Jerome B., additional, Preston, Gloria A., additional, Puccetti, Antonio, additional, Radford, Kristen, additional, Ramos-Casals, Manuel, additional, Rao, V. Koneti, additional, Rauschkolb, Paula K., additional, Reddy, Venkat, additional, Redlich, Kurt, additional, Rival, Claudia, additional, Rose, Noel R., additional, Rosen, Antony, additional, Schrader, John W., additional, Schwaeble, Wilhelm J., additional, Selmi, Carlo, additional, Nida Sen, H., additional, Serota, Marc, additional, Sheikh, Kazim A., additional, Shoenfeld, Yehuda, additional, Shortman, Ken, additional, Sieper, Joachim, additional, Silverstein, Arthur M., additional, Sim, Robert B., additional, Simon, Anna, additional, Smolen, Josef S., additional, Sollid, Ludvig M., additional, Stoffels, Monique, additional, Su, Helen, additional, Syrbe, Uta, additional, Talwalkar, Jayant A., additional, Taneja, Veena, additional, Tincani, Angela, additional, Tipping, Peter, additional, Toh, Ban-Hock, additional, Tsokos, George C., additional, Tu, Eric, additional, Tung, Kenneth S.K., additional, van Driel, Ian R., additional, Vergani, Diego, additional, Vickers, Mark A., additional, Viegas, Stuart, additional, Vincent, Angela, additional, von Andrian, Ulrich H., additional, Herrath, Matthias von, additional, Weetman, Anthony P., additional, Wentworth, John M., additional, Weyand, Cornelia M., additional, Wingender, Gerhard, additional, Zanchetta, Renato, additional, and Zouali, Moncef, additional
Published: 2014
Full Text: View/download PDF

124. Elevated levels of homocysteinesulfinic acid in the plasma of patients with amyotrophic lateral sclerosis: a potential source of excitotoxicity?

Author: Lee, Aven, primary, Arachchige, Buddhika Jayakody, additional, Henderson, Robert, additional, Aylward, James, additional, and McCombe, Pamela Ann, additional
Published: 2021
Full Text: View/download PDF

125. Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan

Author: Ishaq, Hira, primary, Durrani, Talha, additional, Umar, Zainab, additional, Khan, Nemat, additional, McCombe, Pamela, additional, and Ul Haq, Mian Ayaz, additional
Published: 2021
Full Text: View/download PDF

126. Biallelic loss-of-function OBSCN variants predispose individuals to severe, recurrent rhabdomyolysis

Author: Cabrera-Serrano, Macarena, primary, Caccavelli, Laure, additional, Savarese, Marco, additional, Vihola, Anna, additional, Jokela, Manu, additional, Johari, Mridul, additional, Capiod, Thierry, additional, Madrange, Marine, additional, Bugiardini, Enrico, additional, Brady, Stefen, additional, Quinlivan, Ros, additional, Merve, Ashirwad, additional, Scalco, Renata, additional, Hilton-Jones, David, additional, Houlden, Henry, additional, Aydin, Halil, additional, Ceylaner, Serdar, additional, Vockley, Jerry, additional, Taylor, Rhonda, additional, Goullee, Hayley, additional, Ylikallio, Emil, additional, Auranen, Mari, additional, Tyynismaa, Henna, additional, Udd, Bjarne, additional, Davis, Mark, additional, Forrest, Alistair, additional, Bratkovic, Drago, additional, Manton, Nicholas, additional, Robertson, Thomas, additional, McCombe, Pamela, additional, Laing, Nigel, additional, Phillips, Liza, additional, Delonlay, Pascale, additional, and Ravenscroft, Gianina, additional
Published: 2021
Full Text: View/download PDF

127. sj-pdf-1-msj-10.1177_1352458520981300 – Supplemental material for Determinants of therapeutic lag in multiple sclerosis

Author: Izanne Roos, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, J William L Brown, Horakova, Dana, Havrdova, Eva Kubala, Debouverie, Marc, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ciron, Jonathan, Ruet, Aurélie, Ozakbas, Serkan, Seze, Jérôme De, Louapre, Céline, Zephir, Hélène, Sá, Maria José, Sola, Patrizia, Ferraro, Diana, Labauge, Pierre, Defer, Gilles, Bergamaschi, Roberto, Lebrun-Frenay, Christine, Boz, Cavit, Cartechini, Elisabetta, Moreau, Thibault, Laplaud, David, Lechner-Scott, Jeannette, Francois Grand’Maison, Gerlach, Oliver, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo, Pesch, Vincent Van, Wijmeersch, Bart Van, Spitaleri, Daniele LA, Soysal, Aysun, Berger, Eric, Prevost, Julie, Aguera-Morales, Eduardo, McCombe, Pamela, Triviño, Tamara Castillo, Clavelou, Pierre, Pelletier, Jean, Turkoglu, Recai, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Sidhom, Youssef, Gouider, Riadh, Tunde Csepany, Bourre, Bertrand, Abdullatif Al Khedr, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Jean-Philippe Camdessanche, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Coles, Alasdair, Malpas, Charles B, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, sj-pdf-1-msj-10.1177_1352458520981300 for Determinants of therapeutic lag in multiple sclerosis by Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva Kubala Havrdova, Marc Debouverie, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Gilles Edan, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Jonathan Ciron, Aurélie Ruet, Serkan Ozakbas, Jérôme De Seze, Céline Louapre, Hélène Zephir, Maria José Sá, Patrizia Sola, Diana Ferraro, Pierre Labauge, Gilles Defer, Roberto Bergamaschi, Christine Lebrun-Frenay, Cavit Boz, Elisabetta Cartechini, Thibault Moreau, David Laplaud, Jeannette Lechner-Scott, Francois Grand’Maison, Oliver Gerlach, Murat Terzi, Franco Granella, Raed Alroughani, Gerardo Iuliano, Vincent Van Pesch, Bart Van Wijmeersch, Daniele LA Spitaleri, Aysun Soysal, Eric Berger, Julie Prevost, Eduardo Aguera-Morales, Pamela McCombe, Tamara Castillo Triviño, Pierre Clavelou, Jean Pelletier, Recai Turkoglu, Bruno Stankoff, Olivier Gout, Eric Thouvenot, Olivier Heinzlef, Youssef Sidhom, Riadh Gouider, Tunde Csepany, Bertrand Bourre, Abdullatif Al Khedr, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanche, Aude Maurousset, Ivania Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, Alasdair Coles, Charles B Malpas, Sandra Vukusic, Helmut Butzkueven and Tomas Kalincik in Multiple Sclerosis Journal
Published: 2021
Full Text: View/download PDF

128. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Author: van Rheenen, Wouter, van der Spek, Rick A A, Shireby, Gemma, Whiteman, David C, Olsen, Catherine M, Uitterlinden, Andre G, Hofman, Albert, Rietschel, Marcella, Cichon, Sven, Nöthen, Markus M., Amouyel, Philippe, Consortium, SLALOM, Consortium, PARALS, Hannon, Eilis, Consortium, SLAGEN, Consortium, SLAP, Traynor, Bryan J, Singleton, Andrew B, Mitne Neto, Miguel, Cauchi, Ruben J, Ophoff, Roel A, Wiedau-Pazos, Martina, Lomen-Hoerth, Catherine, van Deerlin, Vivianna M, Moisse, Matthieu, Grosskreutz, Julian, Roediger, Annekathrin, Gaur, Nayana, Jörk, Alexander, Barthel, Tabea, Theele, Erik, Ilse, Benjamin, Stubendorff, Beatrice, Witte, Otto W, Steinbach, Robert, Baird, Denis, Hübner, Christian A, Graff, Caroline, Brylev, Lev, Fominykh, Vera, Demeshonok, Vera, Ataulina, Anastasia, Rogelj, Boris, Koritnik, Blaž, Zidar, Janez, Ravnik-Glavač, Metka, Restuadi, Restuadi, Glavač, Damjan, Stević, Zorica, Drory, Vivian, Povedano, Monica, Blair, Ian P, Kiernan, Matthew C, Benyamin, Beben, Henderson, Robert D, Furlong, Sarah, Mathers, Susan, Dolzhenko, Egor, McCombe, Pamela A, Needham, Merrilee, Ngo, Shyuan T, Nicholson, Garth A, Pamphlett, Roger, Rowe, Dominic B, Steyn, Frederik J, Williams, Kelly L, Mather, Karen A, Sachdev, Perminder S, Dekker, Annelot M, Henders, Anjali K, Wallace, Leanne, de Carvalho, Mamede, Pinto, Susana, Petri, Susanne, Weber, Markus, Rouleau, Guy A, Silani, Vincenzo, Curtis, Charles J, Breen, Gerome, Gawor, Klara, Glass, Jonathan D, Brown, Robert H, Landers, John E, Shaw, Christopher E, Andersen, Peter M, Groen, Ewout J N, van Es, Michael A, Pasterkamp, R Jeroen, Fan, Dongsheng, Garton, Fleur C, Westeneng, Henk-Jan, McRae, Allan F, Davey Smith, George, Gaunt, Tom R, Eberle, Michael A, Mill, Jonathan, McLaughlin, Russell L, Hardiman, Orla, Kenna, Kevin P, Wray, Naomi R, Tsai, Ellen, Tazelaar, Gijs H P, Runz, Heiko, Franke, Lude, Al-Chalabi, Ammar, Van Damme, Philip, van den Berg, Leonard H, Veldink, Jan H, Comi, Giancarlo, Riva, Nilo, Lunetta, Christian, Gerardi, Francesca, Bakker, Mark K, van Eijk, Kristel R, Cotelli, Maria Sofia, Rinaldi, Fabrizio, Chiveri, Luca, Guaita, Maria Cristina, Perrone, Patrizia, Ceroni, Mauro, Diamanti, Luca, Ferrarese, Carlo, Tremolizzo, Lucio, Delodovici, Maria Luisa, Kooyman, Maarten, Bono, Giorgio, Canosa, Antonio, Manera, Umberto, Vasta, Rosario, Bombaci, Alessandro, Casale, Federico, Fuda, Giuseppe, Salamone, Paolina, Iazzolino, Barbara, Peotta, Laura, Byrne, Ross P, Cugnasco, Paolo, De Marco, Giovanni, Torrieri, Maria Claudia, Palumbo, Francesca, Gallone, Salvatore, Barberis, Marco, Sbaiz, Luca, Gentile, Salvatore, Mauro, Alessandro, Mazzini, Letizia, Doherty, Mark, De Marchi, Fabiola, Corrado, Lucia, D'Alfonso, Sandra, Bertolotto, Antonio, Gionco, Maurizio, Leotta, Daniela, Odddenino, Enrico, Imperiale, Daniele, Cavallo, Roberto, Pignatta, Pietro, Heverin, Mark, De Mattei, Marco, Geda, Claudio, Papurello, Diego Maria, Gusmaroli, Graziano, Comi, Cristoforo, Labate, Carmelo, Ruiz, Luigi, Ferrandi, Delfina, Rota, Eugenia, Aguggia, Marco, Al Khleifat, Ahmad, Di Vito, Nicoletta, Meineri, Piero, Ghiglione, Paolo, Launaro, Nicola, Dotta, Michele, Di Sapio, Alessia, Giardini, Guido, Tiloca, Cinzia, Peverelli, Silvia, Taroni, Franco, Iacoangeli, Alfredo, Pensato, Viviana, Castellotti, Barbara, Comi, Giacomo P, Del Bo, Roberto, Gagliardi, Stella, Raggi, Flavia, Simoncini, Costanza, Shatunov, Aleksey, Lo Gerfo, Annalisa, Inghilleri, Maurizio, Ferlini, Alessandra, Simone, Isabella L, Passarella, Bruno, Guerra, Vito, Zoccolella, Stefano, Nozzoli, Cecilia, Mundi, Ciro, Leone, Maurizio, Ticozzi, Nicola, Zarrelli, Michele, Tamma, Filippo, Valluzzi, Francesco, Calabrese, Gianluigi, Boero, Giovanni, Rini, Augusto, Cooper-Knock, Johnathan, van Vugt, Joke J F A, Smith, Bradley N, Gromicho, Marta, Chandran, Siddharthan, Pal, Suvankar, Morrison, Karen E, Shaw, Pamela J, Hardy, John, Orrell, Richard W, Sendtner, Michael, Meyer, Thomas, Hop, Paul J, Başak, Nazli, van der Kooi, Anneke J, Ratti, Antonia, Fogh, Isabella, Gellera, Cinzia, Lauria, Giuseppe, Corti, Stefania, Cereda, Cristina, Sproviero, Daisy, Zwamborn, Ramona A J, Sorarù, Gianni, Siciliano, Gabriele, Filosto, Massimiliano, Padovani, Alessandro, Chiò, Adriano, Calvo, Andrea, Moglia, Cristina, Brunetti, Maura, Grassano, Maurizio, de Klein, Niek, Beghi, Ettore, Pupillo, Elisabetta, Logroscino, Giancarlo, Nefussy, Beatrice, Osmanovic, Alma, Nordin, Angelica, Lerner, Yossef, Zabari, Michal, Gotkine, Marc, Baloh, Robert H, Westra, Harm-Jan, Bell, Shaughn, Vourc'h, Patrick, Corcia, Philippe, Couratier, Philippe, Millecamps, Stéphanie, Meininger, Vincent, Salachas, François, Mora Pardina, Jesus S, Assialioui, Abdelilah, Rojas-García, Ricardo, Bakker, Olivier B, Dion, Patrick A, Ross, Jay P, Ludolph, Albert, Weishaupt, Jochen H, Brenner, David, Freischmidt, Axel, Bensimon, Gilbert, Brice, Alexis, Dürr, Alexandra, Payan, Christine A M, Deelen, Patrick, Saker-Delye, Safa, Wood, Nicholas W, Topp, Simon, Rademakers, Rosa, Tittmann, Lukas, Lieb, Wolfgang, Franke, Andre, Ripke, Stephan, Braun, Alice, and Kraft, Julia
Subjects: ddc:570, Genetics, Medizin
Abstract: In the version of this article initially published, the affiliation for Nazli Başak appeared incorrectly. Nazli Başak is at Koç University, School of Medicine, KUTTAM-NDAL, Istanbul, Turkey, and not Bogazici University. The error has been corrected in the HTML and PDF versions of the article.
Published: 2021

129. Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders

Author: Nabais, Marta F., Laws, Simon M., Lin, Tian, Vallerga, Costanza L., Armstrong, Nicola J., Blair, Ian P., Kwok, John B., Mather, Karen A., Mellick, George D., Sachdev, Perminder S., Wallace, Leanne, Henders, Anjali K., Zwamborn, Ramona A. J., Hop, Paul J., Lunnon, Katie, Pishva, Ehsan, Roubroeks, Janou A. Y., Soininen, Hilkka, Tsolaki, Magda, Mecocci, Patrizia, Lovestone, Simon, Kłoszewska, Iwona, Vellas, Bruno, Furlong, Sarah, Garton, Fleur C., Henderson, Robert D., Mathers, Susan, McCombe, Pamela A., Needham, Merrilee, Ngo, Shyuan T., Nicholson, Garth, Pamphlett, Roger, Rowe, Dominic B., Steyn, Frederik J., Williams, Kelly L., Anderson, Tim J., Bentley, Steven R., Dalrymple-Alford, John, Fowder, Javed, Gratten, Jacob, Halliday, Glenda, Hickie, Ian B., Kennedy, Martin, Lewis, Simon J. G., Montgomery, Grant W., Pearson, John, Pitcher, Toni L., Silburn, Peter, Zhang, Futao, Visscher, Peter M., Yang, Jian, Stevenson, Anna J., Hillary, Robert F., Marioni, Riccardo E., Harris, Sarah E., Deary, Ian J., Jones, Ashley R., Shatunov, Aleksey, Iacoangeli, Alfredo, van Rheenen, Wouter, van den Berg, Leonard H., Shaw, Pamela J., Shaw, Cristopher E., Morrison, Karen E., Al-Chalabi, Ammar, Veldink, Jan H., Hannon, Eilis, Mill, Jonathan, Wray, Naomi R., McRae, Allan F., the Alzheimer's Disease Neuroimaging Initiative, the Australian Imaging Biomarkers and Lifestyle study, Nabais, Marta F., Laws, Simon M., Lin, Tian, Vallerga, Costanza L., Armstrong, Nicola J., Blair, Ian P., Kwok, John B., Mather, Karen A., Mellick, George D., Sachdev, Perminder S., Wallace, Leanne, Henders, Anjali K., Zwamborn, Ramona A. J., Hop, Paul J., Lunnon, Katie, Pishva, Ehsan, Roubroeks, Janou A. Y., Soininen, Hilkka, Tsolaki, Magda, Mecocci, Patrizia, Lovestone, Simon, Kłoszewska, Iwona, Vellas, Bruno, Furlong, Sarah, Garton, Fleur C., Henderson, Robert D., Mathers, Susan, McCombe, Pamela A., Needham, Merrilee, Ngo, Shyuan T., Nicholson, Garth, Pamphlett, Roger, Rowe, Dominic B., Steyn, Frederik J., Williams, Kelly L., Anderson, Tim J., Bentley, Steven R., Dalrymple-Alford, John, Fowder, Javed, Gratten, Jacob, Halliday, Glenda, Hickie, Ian B., Kennedy, Martin, Lewis, Simon J. G., Montgomery, Grant W., Pearson, John, Pitcher, Toni L., Silburn, Peter, Zhang, Futao, Visscher, Peter M., Yang, Jian, Stevenson, Anna J., Hillary, Robert F., Marioni, Riccardo E., Harris, Sarah E., Deary, Ian J., Jones, Ashley R., Shatunov, Aleksey, Iacoangeli, Alfredo, van Rheenen, Wouter, van den Berg, Leonard H., Shaw, Pamela J., Shaw, Cristopher E., Morrison, Karen E., Al-Chalabi, Ammar, Veldink, Jan H., Hannon, Eilis, Mill, Jonathan, Wray, Naomi R., McRae, Allan F., the Alzheimer's Disease Neuroimaging Initiative, and the Australian Imaging Biomarkers and Lifestyle study
Abstract: Background: People with neurodegenerative disorders show diverse clinical syndromes, genetic heterogeneity, and distinct brain pathological changes, but studies report overlap between these features. DNA methylation (DNAm) provides a way to explore this overlap and heterogeneity as it is determined by the combined effects of genetic variation and the environment. In this study, we aim to identify shared blood DNAm differences between controls and people with Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. Results: We use a mixed-linear model method (MOMENT) that accounts for the effect of (un)known confounders, to test for the association of each DNAm site with each disorder. While only three probes are found to be genome-wide significant in each MOMENT association analysis of amyotrophic lateral sclerosis and Parkinson’s disease (and none with Alzheimer’s disease), a fixed-effects meta-analysis of the three disorders results in 12 genome-wide significant differentially methylated positions. Predicted immune cell-type proportions are disrupted across all neurodegenerative disorders. Protein inflammatory markers are correlated with profile sum-scores derived from disease-associated immune cell-type proportions in a healthy aging cohort. In contrast, they are not correlated with MOMENT DNAm-derived profile sum-scores, calculated using effect sizes of the 12 differentially methylated positions as weights. Conclusions: We identify shared differentially methylated positions in whole blood between neurodegenerative disorders that point to shared pathogenic mechanisms. These shared differentially methylated positions may reflect causes or consequences of disease, but they are unlikely to reflect cell-type proportion differences.
Published: 2021

130. Efficacy of Cladribine Tablets as a Treatment for People with Multiple Sclerosis : Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-Term Efficacy and Biomarker Australian Study)

Author: Maltby, Vicki E., Lea, Rodney A., Monif, Mastura, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Butzkueven, Helmut, Barnett, Michael, Lechner-Scott, Jeannette, Maltby, Vicki E., Lea, Rodney A., Monif, Mastura, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Butzkueven, Helmut, Barnett, Michael, and Lechner-Scott, Jeannette
Abstract: Background: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing schedule is for 2 courses given a year apart, which has been shown to be effective for treatment of MS for up to 4 years in 75% of patients (based on annualized relapse rate). However, the reinitiation of therapy after year 4 has not been studied. Objective: This study aims to evaluate the safety and efficacy of cladribine tablets over a 6-year period, according to no evidence of disease activity 3. Methods: This will be a multicenter, 6-year, phase IV, low interventional, observational study that incorporates clinical, hematological, biochemical, epigenetic, radiological and cognitive biomarkers of disease. Participants considered for treatment with cladribine as part of their routine clinical care will be consented to take part in the study. They will be monitored at regular intervals during the initial course of medication administration in years 1 and 2. After year 3, patients will have the option of redosing, if clinically indicated, or to switch to another disease-modifying therapy. Throughout the duration of the study, we will assess blood-based biomarkers including lymphocyte subsets, serum neurofilament light chain, DNA methylation, and RNA analysis as well as magnetic resonance imaging findings (brain volume and/or lesion load) and cognitive performance. Results: This study has been approved by the Hunter New England Local Health District Human Research Ethics Committee. Recruitment began in March of 2019 and was completed by June 2021. Conclusions: This will be the first long-Term efficacy trial of cladribine, which offers reinitiation of therapy in the 3rd year, based on disease activity, after the initial 2 courses. We expect that this study will indicate whether any of the assessed biomarkers can be used to predict tr
Published: 2021

131. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Author: UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, Butzkueven, Helmut, MSBase Study Group, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, Butzkueven, Helmut, and MSBase Study Group
Abstract: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43-0.82, = 0.0016), worsening of disability (0.56, 0.38-0.82, = 0.0026), and progress to EDSS step 6 (0.33, 0.19-0.59, = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, = 10) and worsening of disability (0.81, 0.67-0.99, = 0.043). Continued treatment with MS immunotherapies reduces disability accrual by 19%-44% (95% CI 1%-62%), the risk of need of a walking aid by 67% (95% CI 41%-81%), and the frequency of relapses by 40-41% (95% CI 18%-57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
Published: 2021

132. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author: Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, Magyari, Melinda, Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, and Magyari, Melinda
Abstract: Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.
Published: 2021

133. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts

Author: Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, and Magyari, Melinda
Abstract: Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score < 4 (0.75; 0.64–0.88), < 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36
Published: 2021

134. Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with Amyotrophic Lateral Sclerosis

Author: Projectafdeling ALS, Brain, Neurologen, Regenerative Medicine and Stem Cells, Holdom, Cory J, Janse van Mantgem, Mark R, van Eijk, Ruben P A, Howe, Stephanie L, van den Berg, Leonard H, McCombe, Pamela A, Henderson, Robert D, Ngo, Shyuan T, Steyn, Frederik J, Projectafdeling ALS, Brain, Neurologen, Regenerative Medicine and Stem Cells, Holdom, Cory J, Janse van Mantgem, Mark R, van Eijk, Ruben P A, Howe, Stephanie L, van den Berg, Leonard H, McCombe, Pamela A, Henderson, Robert D, Ngo, Shyuan T, and Steyn, Frederik J
Published: 2021

135. Guillain-Barré Syndrome: Modern Theories of Etiology

Author: Hardy, Todd A., Blum, Stefan, McCombe, Pamela A., and Reddel, Stephen W.
Published: 2011
Full Text: View/download PDF

136. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions

Author: Blum, Stefan and McCombe, Pamela A.
Published: 2014
Full Text: View/download PDF

137. Increased expression of the hypoxia-related genes in peripheral blood leukocytes of human subjects with acute ischemic stroke

Author: Yan, Jun, Liu, Jia, Greer, Judith M., and McCombe, Pamela A.
Published: 2014
Full Text: View/download PDF

138. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

Author: Diouf, Ibrahima, Malpas, Charles B, Sharmin, Sifat, Roos, Izanne, Horakova, Dana, Kubala Havrdova, Eva, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Yamout, Bassem, Altintas, Ayse, Gerlach, Oliver, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Karabudak, Rana, Iuliano, Gerardo, McGuigan, Christopher, Cartechini, Elisabetta, Hughes, Stella, Sa, Maria Jose, Solaro, Claudio, Kappos, Ludwig, Hodgkinson, Suzanne, Slee, Mark, Granella, Franco, de Gans, Koen, McCombe, Pamela A, Ampapa, Radek, van der Walt, Anneke, Butzkueven, Helmut, Sánchez-Menoyo, José Luis, Vucic, Steve, Laureys, Guy, Sidhom, Youssef, Gouider, Riadh, Castillo-Trivino, Tamara, Gray, Orla, Aguera-Morales, Eduardo, Al-Asmi, Abdullah, Shaw, Cameron, Al-Harbi, Talal M, Csepany, Tunde, Sempere, Angel P, Treviño Frenk, Irene, Stuart, Elizabeth A, and Kalincik, Tomas
Abstract: BackgroundSimultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. Here we emulate a randomised trial simultaneously comparing the effectiveness of six commonly used therapies over 5 years.MethodsData from 74 centres in 35 countries were sourced from MSBase. For each patient, the first eligible intervention was analysed, censoring at change/discontinuation of treatment. The compared interventions included natalizumab, fingolimod, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate and no treatment. Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement.Results23 236 eligible patients were diagnosed with RRMS or clinically isolated syndrome. Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). Further, natalizumab (HR=0.43, 95% CI=0.32 to 0.56) showed a superior ATE in reducing disability worsening and in disability improvement (HR=1.32, 95% CI=1.08 to 1.60). The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability.ConclusionsThe effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously.
Published: 2023
Full Text: View/download PDF

139. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

Author: Signori, Alessio, Lorscheider, Johannes, Vukusic, Sandra, Trojano, Maria, Iaffaldano, Pietro, Hillert, Jan, Hyde, Robert, Pellegrini, Fabio, Magyari, Melinda, Koch-Henriksen, Nils, Sørensen, Per Soelberg, Spelman, Tim, van der Walt, Anneke, Horakova, Dana, Havrdova, Eva, Girard, Marc, Eichau, Sara, Grand'Maison, Francois, Gerlach, Oliver, Terzi, Murat, Ozakbas, Serkan, Skibina, Olga, Van Pesch, Vincent, Sa, Maria Jose, Prevost, Julie, Alroughani, Raed, McCombe, Pamela A, Gouider, Riadh, Mrabet, Saloua, Castillo-Trivino, Tamara, Zhu, Chao, de Gans, Koen, Sánchez-Menoyo, José Luis, Yamout, Bassem, Khoury, Samia, Sormani, Maria Pia, Kalincik, Tomas, and Butzkueven, Helmut
Abstract: BackgroundOver the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time.MethodsAll patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3–4.ResultsA total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria.ConclusionsContrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.
Published: 2023
Full Text: View/download PDF

140. Effect of immunotherapy on intracranial EEG in patients with seronegative autoimmune‐associated epilepsy

Author: Gillinder, Lisa, Papacostas, Jason, McCombe, Pamela, and Chauvel, Patrick
Abstract: Objective. Immunity is increasingly implicated in the aetiology of certain types of epilepsy, however, the clinical and EEG features in such cases remain poorly defined. We present stereo‐electroencephalography (SEEG) findings in patients who were thought to have autoantibody‐mediated epilepsy on the basis of clinical improvement after administration of immunotherapy (IT). Methods. All patients undergoing SEEG implantation in our service were reviewed and those receiving immunotherapy, either before, during, or after SEEG evaluation, were identified. Response to immunotherapy was defined as greater than 50% seizure reduction. We compared the clinical features and SEEG findings between those who responded to immunotherapy and those who did not. Results. Sixty‐two cases underwent SEEG evaluation. Of these, 11 received immunotherapy and three cases demonstrated a positive clinical benefit. The three responsive patients had multifocal seizure onset, repetitive spiking interictally and ictally, perisylvian semiology, seizure onset in the posterior perisylvian regions, and normal neuroimaging. Significance. Seronegative immunotherapy responders exist in epilepsy populations, therefore the diagnosis of autoimmune‐associated epilepsy should be considered before proceeding to epilepsy surgery. Possible features of an electroclinical syndrome associated with autoimmunity may include multifocal seizure onset, perisylvian involvement, and normal neuroimaging.
Published: 2022
Full Text: View/download PDF

141. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Author: Wilkins, Alastair, Slee, Mark, TERZİ, MURAT, Grand'Maison, Francois, Ferraro, Diana, Sola, Patrizia, Van Pesch, Vincent, McCombe, Pamela, Hupperts, Raymond, Alroughani, Raed, Grammond, Pierre, Bergamaschi, Roberto, Lugaresi, Alessandra, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Pearson, Owen R., Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Butzkueven, Helmut, Kalincik, Tomas, Onofrj, Marco, Trojano, Maria, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Izquierdo, Guillermo, Havrdova, Eva, Horakova, Dana, Zwanikken, Cees, Soysal, Aysun, Yamout, Bassem, Piroska, Imre, McDonnell, Gavin, Moore, Fraser, Butler, Ernest, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hodgkinson, Suzanne, Oreja-Guevara, Celia, BOZ, CAVİT, Prevost, Julie, Olascoaga, Javier, Van Wijmeersch, Bart, Barnett, Michael, Verheul, Freek, Rojas, Juan Ingacio, Spitaleri, Daniele, Rio, Maria Edite, Taylor, Bruce, Luis Sanchez-Menoyo, Jose, Ramo-Tello, Cristina, Solaro, Claudio, Csepany, Tunde, Iuliano, Gerardo, Skibina, Olga, Petersen, Thor, Bolanos, Ricardo Fernandez, Sidhom, Youssef, Riadh, Riadh, Vucic, Steve, Macdonell, Richard, Sempere, Angel Perez, Simo, Magdolna, Kister, Ilya, Shuey, Neil, Radek, Radek, Dominguez, Jose Andres, Pia Amato, Maria, Saladino, Maria Laura, Kermode, Allan, Brown, J. William L., Coles, Alasdair, Lechner-Scott, Jeannette, Willis, Mark, Rice, Claire, Scolding, Neil, Flechter, Schlomo, Harding, Katharine, Jones, Joanne, Robertson, Neil, Hughes, Stella, ÖZAKBAŞ, SERKAN, Brown, J William L, Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessandra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francoi, Terzi, Murat, Lechner-Scott, Jeannette, Flechter, Schlomo, Slee, Mark, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Willis, Mark, Rice, Claire, Scolding, Neil, Wilkins, Alastair, Pearson, Owen R, Ziemssen, Tjalf, Hutchinson, Michael, Harding, Katharine, Jones, Joanne, McGuigan, Christopher, Butzkueven, Helmut, Kalincik, Toma, Robertson, Neil, Brown, Will [0000-0002-7737-5834], Coles, Alasdair [0000-0003-4738-0760], Jones, Joanna [0000-0003-4974-1371], Apollo - University of Cambridge Repository, DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, and OMÜ
Subjects: Male, INTERFERON-BETA, MULTICENTER, Interferon-beta/therapeutic use, multiple sclerosis, 01 natural sciences, Cohort Studies, 0302 clinical medicine, Natalizumab, 030212 general & internal medicine, Alemtuzumab, Original Investigation, GLATIRAMER ACETATE, NATALIZUMAB, Natalizumab/therapeutic use, OUTCOMES, treatment, ALEMTUZUMAB, Absolute risk reduction, General Medicine, Immunologic Factors/therapeutic use, Fingolimod, TIME, Disease Progression, Female, Immunosuppressive Agents, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Alemtuzumab/therapeutic use, Lower risk, Time-to-Treatment, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, Internal medicine, medicine, Humans, Immunologic Factors, 0101 mathematics, Glatiramer acetate, Fingolimod Hydrochloride/therapeutic use, business.industry, Fingolimod Hydrochloride, Multiple sclerosis, DISABILITY, 010102 general mathematics, Glatiramer Acetate, Interferon-beta, Multiple Sclerosis, Relapsing-Remitting/drug therapy, medicine.disease, FINGOLIMOD, Immunosuppressive Agents/therapeutic use, multiple sclerosis, progression, treatment, progression, business, Glatiramer Acetate/therapeutic use
Abstract: none 40 si his study was financially supported by National Health and Medical Research Council of Australia (fellowships 1140766 and 1080518, project grants 1129189 and 1083539), the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship), a Next Generation Fellowship funded by the Grand Charity of the Freemason’s (recipient JWLB), and the MSBase 2017 Fellowship (recipient JWLB). Alemtuzumab studies done in Cambridge were supported by the NIHR Cambridge Biomedical Research Centre and the MS Society UK. The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme, and Teva. IMPORTANCE: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition. OBJECTIVE: To determine the association between the use, the type of, and the timing of DMTs with the risk of conversion to secondary progressive MS diagnosed with a validated definition. DESIGN, SETTING, AND PARTICIPANTS: Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical monitoring) between 1988-2012 with minimum 4 years' follow-up. EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). MAIN OUTCOME AND MEASURE: Conversion to objectively defined secondary progressive MS. RESULTS: Of the 1555 patients, 1123 were female (mean baseline age, 35 years [SD, 10]). Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to secondary progressive MS than matched untreated patients (HR, 0.71; 95% CI, 0.61-0.81; P
Published: 2019

142. Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia

Author: Restuadi, Restuadi, primary, Garton, Fleur C., additional, Benyamin, Beben, additional, Lin, Tian, additional, Williams, Kelly L., additional, Vinkhuyzen, Anna, additional, van Rheenen, Wouter, additional, Zhu, Zhihong, additional, Laing, Nigel G., additional, Mather, Karen A., additional, Sachdev, Perminder S., additional, Ngo, Shyuan T., additional, Steyn, Frederik J., additional, Wallace, Leanne, additional, Henders, Anjali K., additional, Visscher, Peter M., additional, Needham, Merrilee, additional, Mathers, Susan, additional, Nicholson, Garth, additional, Rowe, Dominic B., additional, Henderson, Robert D., additional, McCombe, Pamela A., additional, Pamphlett, Roger, additional, Blair, Ian P., additional, Wray, Naomi R., additional, and McRae, Allan F., additional
Published: 2021
Full Text: View/download PDF

143. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Author: Sharmin, Sifat, primary, Lefort, Mathilde, additional, Andersen, Johanna Balslev, additional, Leray, Emmanuelle, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Alroughani, Raed, additional, Ayuso, Guillermo Izquierdo, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand’Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Prevost, Julie, additional, Maimone, Davide, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Van der Walt, Anneke, additional, Van Wijmeersch, Bart, additional, Csepany, Tunde, additional, Spitaleri, Daniele Litterio A., additional, Vucic, Ostoja (Steve), additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérôme, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun-Frénay, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Maurousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Laplaud, David, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn Thorup, additional, Soerensen, Per Soelberg, additional, Pfleger, Claudia Christina, additional, Rasmussen, Peter Vestergaard, additional, Jensen, Michael Broksgaard, additional, Frederiksen, Jette Lautrup, additional, Bramow, Stephan, additional, Mathiesen, Henrik Kahr, additional, Schreiber, Karen Ingrid, additional, Magyari, Melinda, additional, Vukusic, Sandra, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

144. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Author: Diouf, Ibrahima, primary, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Ayuso, Guillermo Izquierdo, additional, Madueño, Sara Eichau, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Butzkueven, Helmut, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Van Pesch, Vincent, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Christopher, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria Jose, additional, Kappos, Ludwig, additional, Ramo-Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele Litterio A., additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, Verheul, Freek, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Skibina, Olga, additional, Prevost, Julie, additional, Sinnige, L, additional, Sanchez-Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Kister, Ilya, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

145. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

Author: Harding-Forrester, Sam, primary, Roos, Izanne, additional, Sharmin, Sifat, additional, Diouf, Ibrahima, additional, Malpas, Charles, additional, Nguyen, Ai-Lan, additional, Moradi, Nahid, additional, Horáková, Dana, additional, Havrdová, Eva Kubala, additional, Patti, Francesco, additional, Ayuso, Guillermo Izquierdo, additional, Madueño, Sara Eichau, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grand’Maison, Francois, additional, Weinstock-Guttman, Bianca, additional, Amato, Maria Pia, additional, Grammond, Pierre, additional, Gerlach, Oliver, additional, Ozakbas, Serkan, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Butzkueven, Helmut, additional, Lechner-Scott, Jeannette, additional, Boz, Cavit, additional, Alroughani, Raed, additional, Van Pesch, Vincent, additional, Cartechini, Elisabetta, additional, Terzi, Murat, additional, Maimone, Davide, additional, Ramo-Tello, Cristina, additional, Spitaleri, Daniele Litterio A., additional, Kappos, Ludwig, additional, Yamout, Bassem, additional, Sá, Maria José, additional, Slee, Mark, additional, Morgado, Yolanda Blanco, additional, Bergamaschi, Roberto, additional, Butler, Ernest, additional, Iuliano, Gerardo, additional, Granella, Franco, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, Karabudak, Rana, additional, Prevost, Julie, additional, Sánchez-Menoyo, José Luis, additional, De Gans, Koen, additional, McCombe, Pamela, additional, Castillo-Triviño, Tamara, additional, Macdonell, Richard, additional, Altintas, Ayse, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Van Der Walt, Anneke, additional, Vucic, Steve, additional, Türkoǧlu, Recai, additional, Barnett, Michael, additional, Cristiano, Edgardo, additional, Zakaria, Magd, additional, Shaygannejad, Vahid, additional, Hodgkinson, Suzanne, additional, Soysal, Aysun, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

146. Real-world Experience with Cladribine Tablets in the MSBase Registry (2942)

Author: Butzkueven, Helmut, primary, Spelman, Timothy, additional, Hodgkinson, Suzanne, additional, Kalincik, Tomas, additional, Buzzard, Katherine, additional, Skabina, Olga, additional, Madueño, Sara Eichau, additional, Ayuso, Guillermo Izquierdo, additional, Van der Walt, Anneke, additional, Grand-Maison, Francois, additional, Butler, Ernest, additional, Prevost, Julie, additional, McCombe, Pamela, additional, Oh, Jiwon, additional, Macdonell, Richard, additional, Lechner-Scott, Jeannette, additional, Van Pesch, Vincent, additional, Duquette, Pierre, additional, Prat, Alexandre, additional, Girard, Marc, additional, Kermode, Allan, additional, and Fabris, Jessica, additional
Published: 2021
Full Text: View/download PDF

147. Delay from treatment start to full effect of immunotherapies for multiple sclerosis (2679)

Author: Roos, Izanne, primary, Leray, Emmanuelle, additional, Frascoli, Federico, additional, Casey, Romain, additional, Brown, J William, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Madueño, Sara Eichau, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Prat, Alexandre, additional, Girard, Marc, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Ozakbas, Serkan, additional, Bergamaschi, Roberto, additional, Sa, Maria Jose, additional, Cartechini, Elisabetta, additional, Boz, Cavit, additional, Granella, Franco, additional, Gerlach, Oliver, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Spitaleri, Daniele Litterio A., additional, Van Pesch, Vincent, additional, Soysal, Aysun, additional, Olascoaga, Javier, additional, Prevost, Julie, additional, Morales, Eduardo Aguera, additional, Slee, Mark, additional, Csepany, Tunde, additional, Turkoglu, Recai, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Van Wijmeersch, Bart, additional, McCombe, Pamela, additional, Macdonell, Richard, additional, Coles, Alasdair, additional, Malpas, Charles, additional, Butzkueven, Helmut, additional, Vukusic, Sandra, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

148. MRI Patterns Distinguish Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis (4128)

Author: Clarke, Laura, primary, Arnett, Simon, additional, Bukhari, Wajih, additional, Khalilidehkordi, Elham, additional, Sanchez, Sofia Jimenez, additional, O’Gorman, Cullen, additional, Prain, Kerri, additional, Woodhall, Mark, additional, Silvestrini, Roger, additional, Bundell, Christine, additional, Abernethy, David, additional, Bhuta, Sandeep, additional, Blum, Stefan, additional, Boggild, Mike, additional, Boundy, Karyn, additional, Brew, Bruce, additional, Brownlee, Wallace, additional, Butzkueven, Helmut, additional, Carroll, William, additional, Chen, Celia, additional, Coulthard, Alan, additional, Dale, Russell, additional, Das, Chandi, additional, Fabis-Pedrini, Marzena, additional, Fulcher, David, additional, Gillis, David, additional, Hawke, Simon, additional, Heard, Robert, additional, Henderson, Andrew, additional, Heshmat, Saman, additional, Hodgkinson, Suzanne, additional, Kilpatrick, Trevor, additional, King, John, additional, Kneebone, Christopher, additional, Kornberg, Andrew, additional, Lechner-Scott, Jeannette, additional, Lin, Ming-Wei, additional, Lynch, Christopher, additional, Macdonell, Richard, additional, Mason, Deborah, additional, McCombe, Pamela, additional, Pereira, Jennifer, additional, Pollard, John, additional, Ramanathan, Sudarshini, additional, Reddel, Stephen, additional, Shaw, Cameron, additional, Spies, Judith, additional, Stankovich, James, additional, Sutton, Ian, additional, Vucic, Steve, additional, Walsh, Michael, additional, Wong, Richard, additional, Yiu, Eppie, additional, Barnett, Michael, additional, Kermode, Allan, additional, Marriott, Mark, additional, Parratt, John, additional, Slee, Mark, additional, Taylor, Bruce, additional, Willoughby, Ernest, additional, Brilot, Fabienne, additional, Vincent, Angela, additional, Waters, Patrick, additional, and Broadley, Simon, additional
Published: 2021
Full Text: View/download PDF

149. Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Author: Rheenen, Wouter van, primary, Spek, Rick van der, additional, Bakker, Mark, additional, Berg, Leonard van den, additional, Veldink, Jan, additional, Vugt, Joke van, additional, Hop, Paul, additional, Zwamborn, Ramona, additional, de Klein, Niek, additional, Westra, Harm-Jan, additional, Bakker, Olivier, additional, Deelen, Patrick, additional, Shireby, Gemma, additional, Hannon, Eilis, additional, Moisse, Matthieu, additional, Baird, Denis, additional, Restuadi, Restuadi, additional, Dolzhenko, Egor, additional, Dekker, Annelot, additional, Gawor, Klara, additional, Westeneng, Henk-Jan, additional, Tazelaar, Gijs, additional, Eijk, Kristel van, additional, Kooyman, Maarten, additional, Byrne, Ross, additional, Doherty, Mark, additional, Heverin, Mark, additional, Khleifat, Ahmad Al, additional, Iacoangeli, Alfredo, additional, Shatunov, Aleksey, additional, Ticozzi, Nicola, additional, Cooper-Knock, Johnathan, additional, Smith, Bradley, additional, Gromicho, Marta, additional, Chandran, Siddharthan, additional, Pal, Suvankar, additional, Morrison, Karen, additional, Shaw, Pamela, additional, Hardy, John, additional, Orrell, Richard, additional, Sendtner, Michael, additional, Meyer, Thomas, additional, Basak, Nazli, additional, Kooi, Anneke van der, additional, Ratti, Antonia, additional, Fogh, Isabella, additional, Gellera, Cinzia, additional, Pinter, Guiseppe Lauria, additional, Corti, Stefania, additional, Cereda, Cristina, additional, Sproviero, Daisy, additional, D'Alfonso, Sandra, additional, Soraru, Gianni, additional, Siciliano, Gabriele, additional, Filosto, Massimiliano, additional, Padovani, Alessandro, additional, Chio, Adriano, additional, Calvo, Andrea, additional, Moglia, Cristina, additional, Brunetti, Maura, additional, Canosa, Antonio, additional, Grassano, Maurizio, additional, Beghi, Ettore, additional, Pupillo, Elisabetta, additional, Logroscino, Giancarlo, additional, Nefussy, Beatrice, additional, Osmanovic, Alma, additional, Nordin, Angelica, additional, Lerner, Yossef, additional, Zabari, Michal, additional, Gotkine, Marc, additional, Baloh, Robert, additional, Bell, Shaugn, additional, Vourc'h, Patrick, additional, Corcia, Philippe, additional, Couratier, Philippe, additional, Millecamps, Stephanie, additional, Meininger, Vincent, additional, Salachas, Francois, additional, Pardina, Jesus Mora, additional, Assialioui, Abdelilah, additional, Rojas-García, Ricardo, additional, Dion, Patrick, additional, Ross, Jay, additional, Ludolph, Albert, additional, Weishaupt, Jochen, additional, Brenner, David, additional, Freischmidt, Axel, additional, Bensimon, Gilbert, additional, Brice, Alexis, additional, Durr, Alexandra, additional, Payan, Christine, additional, Saker-Delye, Safa, additional, Wood, Nicholas, additional, Topp, Simon, additional, Rademakers, Rosa, additional, Tittmann, Lukas, additional, Lieb, Wolfgang, additional, Franke, Andre, additional, Ripke, Stephan, additional, Braun, Alice, additional, Kraft, Julia, additional, Whiteman, David, additional, Olsen, Catherine, additional, Uitterlinden, André, additional, Hofman, Albert, additional, Rietschel, Marcella, additional, Cichon, Sven, additional, Nöthen, Markus, additional, Amouyel, Philippe, additional, Traynor, Bryan, additional, Singleton, Andrew, additional, Neto, Miguel Mitne, additional, Cauchi, Ruben, additional, Ophoff, Roel, additional, Wiedau-Pazos, Martina, additional, Lomen-Hoerth, Catherine, additional, Deerlin, Vivianna Van, additional, Grosskreutz, Julian, additional, Rödiger, Annekathrin, additional, Jörk, Alexander, additional, Barthel, Tabea, additional, Theele, Erik, additional, Ilse, Berjamin, additional, Stubendorff, Beatrice, additional, Witte, Otto, additional, Steinbach, Robert, additional, Hübner, Christian, additional, Graff, Caroline, additional, Brylev, Lev, additional, Fominykh, Vera, additional, Demeshonok, Vera, additional, Ataulina, Anastasia, additional, Rogelj, Boris, additional, Koritnik, Blaž, additional, Zidar, Janez, additional, Ravnik-Glavač, Metka, additional, Glavač, Damjan, additional, Stević, Zorica, additional, Drory, Vivian, additional, Povedano, Mónica, additional, Blair, Ian, additional, Kiernan, Matthew, additional, Benyamin, Beben, additional, Henderson, Robert, additional, Furlong, Sarah, additional, Mathers, Susan, additional, McCombe, Pamela, additional, Needham, Merrilee, additional, Ngo, Shyuan, additional, Nicholson, Garth, additional, Pamphlett, Roger, additional, Rowe, Dominic, additional, Steyn, Frederik, additional, Williams, Kelly, additional, Mather, Karen, additional, Sachdev, Perminder, additional, Henders, Anjali, additional, Wallace, Leanne, additional, de Carvalho, Mamede, additional, Pinto, Susana, additional, Petri, Susanne, additional, Weber, Markus, additional, Rouleau, Guy, additional, Silani, Vincenzo, additional, Curtis, Charles, additional, Breen, Gerome, additional, Glass, Jonathan, additional, Brown, Robert, additional, Landers, John, additional, Shaw, Christopher, additional, Andersen, Peter, additional, Groen, Ewout, additional, Es, Michael van, additional, Pasterkamp, Jeroen, additional, Fan, Dongsheng, additional, Garton, Fleur, additional, McRae, Allan, additional, Smith, George Davey, additional, Gaunt, Tom, additional, Eberle, Michael, additional, Mill, Jonathan, additional, McLaughlin, Russell, additional, Hardiman, Orla, additional, Kenna, Kevin, additional, Wray, Naomi, additional, Tsai, Ellen, additional, Runz, Heiko, additional, Franke, Lude, additional, Al-Chalabi, Ammar, additional, Damme, Philip Van, additional, and Gaur, Nayana, additional
Published: 2021
Full Text: View/download PDF

150. An Australian State-Based Cohort Study of Autoimmune Encephalitis Cases Detailing Clinical Presentation, Investigation Results, and Response to Therapy

Author: Swayne, Andrew, primary, Warren, Nicola, additional, Prain, Kerri, additional, Gillis, David, additional, O'Gorman, Cullen, additional, Tsang, Benjamin K-T., additional, Muller, Claire, additional, Broadley, Simon, additional, Adam, Robert J., additional, McCombe, Pamela, additional, Wong, Richard C., additional, and Blum, Stefan, additional
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

885 results on '"McCombe, Pamela"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources